Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1587, Issue 2-3, 2002, Pages 287-295

  Balzarini, J ^a   McGuigan, C ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antiviral activity; Bicyclic nucleoside analogues; Chemotherapy; Thymidine kinase; Varicella zoster virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; CD 1743; CF 1368; CF 1369; CF 1382; CF 1395; CF 1397; CF 1398; CF 1449; CF 1558; CF 1603; CF 1625; CF 1649; CF 1656; CF 1657; CF 1658; CF 1662; CF 1676; CF 1698; CF 1711; CF 1712; CF 1717; CF 1742; CF 1743; CF 1744; CF 1770; CF 1835; CF 1836; CF 1837; CF 2011; CF 2012; CF 2013; DNA POLYMERASE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; PYROPHOSPHORIC ACID DERIVATIVE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHEMOTHERAPY; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; LIGHT EXPOSURE; LIPOPHILICITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET RADIATION; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELLS, CULTURED; CHICKENPOX; DRUG DESIGN; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MOLECULAR STRUCTURE; PHOSPHORYLATION; PYRIMIDINE NUCLEOSIDES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 0037130292     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(02)00091-1     Document Type: Review

References (39)

1. Targets for the antiviral activity of pyrimidine and purine nucleoside analogues
2. Biochemical aspects of the selective antiherpes activity of nucleoside analogues
3. E-5-(2-bromovinyl)-2′-deoxyuridine: A potent and selective antiherpes agent
4. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus
5. Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2′-deoxyuridines on mouse leukemia L-1210 cell growth
6. Differential affinities of 5-(2-halogenovinyl)-2′-deoxyuridines for deoxythymidine kinases of various origins
7. Characterization of pyrimidine deoxyribonucleoside kinase (thymidine kinase) and thymidylate kinase as a multifunctional enzyme in cells transformed by herpes simplex virus type 1 and in cells infected with mutant strains of herpes simplex virus
8. Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus
9. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex virus type 1 and 2 and varicella-zoster virus
10. Inhibition of thymidylate synthetase by 5-alkynyl-2′-deoxyuridylates
11. 5-substituted 2′-deoxyuridines: Correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase
12. Differential affinities of 5-(halogenovinyl)-2′-deoxyuridines for deoxythymidine kinases of various origins
13. Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir
14. Three-dimensional structure of thymidine kinase from herpes simplex virus type 1
15. The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue
16. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands
17. Structure to 1.9 Å resolution of a complex with herpes simplex virus type-1 thymidine kinase of a novel, non-substrate inhibitor: X-ray crystallographic comparison with binding of aciclovir
18. Evolution of herpesvirus thymidine kinases from cellular deoxycytidine kinase
19. Nucleic acid related compounds: 39. Efficient conversion of 5-iodo to 5-alkynyl and derived 5-substituted uracil bases and nucleosides
20. Nucleic acid related compounds: 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides
21. Palladium-catalysed coupling of terminal alkynes with 5-(trifluoromethanesulfonyloxy)pyrimidine nucleosides
22. Synthesis and properties of 5-(1,2-dihaloethyl)-2′-deoxyuridines and related analogs
23. Steric fixation of bromovinyluracil - Synthesis of furo[2,3-D]pyrimidine nucleosides
24. Synthesis of 5-(1-aridovinyl) and 5-[2-(1-azirinyl)] analogs of 2′-deoxyuridine
25. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base
26. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side-chain
27. Fluorescent bicyclic furo pyrimidine deoxynucleoside analogs as potent and selective inhibitors of VZV and potential future drugs for the treatment of chickenpox and shingles
28. Furano pyrimidines as novel potent and selective anti-VZV agents
29. Bicyclic nucleoside inhibitors of varicella-zoster virus (VZV): The effect of terminal unsaturation in the side chain
30. Bicyclic nucleoside inhibitors of varicella-zoster virus (VZV): The effect of a terminal halogen substitution in the side chain
31. Anti-varicella-zoster virus bicyclic nucleosides: Replacement of furo by pyrro base reduces antiviral potency
32. Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity
33. Antiherpesviral activity and inhibitory action on cell growth of 5-alkenyl derivatives of 1-β-D-arabinofuranosyluracil
34. (E)-5-(2-bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity
35. Synthesis and anti-varicella-zoster virus activity of some novel bicyclic nucleoside inhibitors: Effect of enhanced aqueous solubility
36. Specific recognition of the bicyclic pyrimidine nucleoside analogues, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase
37. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted 2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets
38. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 A resolution
39. Lack of suspectibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase